Affiliation: Memorial Sloan-Kettering Cancer Center
- The role of novel biologics in biliary cancersEmmet Jordan
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Minerva Gastroenterol Dietol 62:325-339. 2016....
- Genomics and pharmacogenomics of pancreatic adenocarcinomaM A Lowery
Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Pharmacogenomics J 12:1-9. 2012....
- Targeted therapies for pancreatic adenocarcinomaM Lowery
Memorial Sloan Kettering Cancer Centre, Weill Medical College of Cornell University, Department of Medicine, GI Oncology ServiceNew York, NY, USA
Minerva Chir 64:501-19. 2009..Herein the authors review the evidence to date for the use of novel cytotoxic and molecularly targeted agents in pancreatic adenocarcinoma, and discuss key areas for future therapeutic development...
- A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinomaMaeve Lowery
Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Gastrointest Cancer 42:160-4. 2011..Individuals who carry a germline mutation in the BRCA 1 or 2 genes have an increased lifetime risk of developing pancreatic adenocarcinoma when compared with the general population...